

SCHEDULING STATUS

4

1. NAME OF THE MEDICINE

DEXILANT 30 mg modified-release capsules, hard

DEXILANT 60 mg modified-release capsules, hard

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each capsule contains 30 mg of dexlansoprazole.

Each capsule contains 60 mg of dexlansoprazole.

Excipients with known effect:

Each 30 mg modified-release capsule contains 68 mg of sucrose.

Each 60 mg modified-release capsule contains 76 mg of sucrose.

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Modified-release capsules, hard

Each 30 mg capsule (size 3) is opaque with a blue cap and a grey body with "TAP" imprinted on the cap and "30" on the body.

Each 60 mg capsule (size 2) is opaque with a blue cap and body with "TAP" imprinted on the cap and "60" on the body.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

DEXILANT is indicated in adults and in adolescents aged 12 to 17 years for the following:

- Treatment of erosive reflux oesophagitis
- Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn for up to 6 months in adults and up to 4 months in adolescents
- Short-term treatment of heartburn and acid regurgitation associated with symptomatic non-erosive gastro-oesophageal reflux disease (GORD)

4.2 Posology and method of administration

Posology

- Treatment of erosive reflux oesophagitis

Adults and adolescents aged 12 to 17 years - The recommended dose is 60 mg once daily for 4 weeks. In patients not fully healed within this time, the treatment may be continued at the same dose for another 4 weeks.

Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn

Adults - The recommended dose is 30 mg once daily for up to 6 months in patients where prolonged acid suppression is needed.

Adolescents aged 12 to 17 years - The recommended dose is 30 mg once daily for up to 4 months in patients where prolonged suppression is needed. Current evidence does not support a specific treatment period time. A decision should be taken by the clinician on a case by case basis.

Symptomatic non-erosive gastro-oesophageal reflux disease (GORD)

Adults and adolescents aged 12 to 17 years - The recommended dose is 30 mg once daily for up to 4 weeks.

Special populations

Elderly

Due to reduced clearance of DEXILANT in the elderly an adjustment of dose may be necessary based on individual requirements. A daily dose of 60 mg should not be exceeded in the elderly unless there are compelling clinical indications (see section 5.2).

Renal impairment

No dosage adjustment is necessary for patients with renal impairment (see section 5.2).

Hepatic impairment

No dosage adjustment is necessary for patients with mild hepatic impairment. Patients with moderate hepatic impairment should be kept under regular supervision and a maximum daily dose of 30 mg should be considered. No studies have been conducted in patients with severe hepatic impairment (see sections 4.4 and 5.2), the use of DEXILANT is not recommended for these patients.

Paediatric population

Adolescents aged 12 to 17 years

Treatment of erosive reflux oesophagitis

The posology of DEXILANT in adolescents aged 12 to 17 years is the same as in adults.

Maintenance of healed erosive reflux oesophagitis and maintenance of relief of heartburn

The dose of DEXILANT in adolescents aged 12 to 17 years is the same as in adults.

Symptomatic non-erosive gastro-oesophageal reflux disease (GORD)

The posology of DEXILANT in adolescents aged 12 to 17 years is the same as in adults.

Children under 12 years of age

The safety and efficacy of DEXILANT in children under 12 years of age have not been established. No data are available.

Method of administration

Oral use.

Capsules should be swallowed whole with liquid. They can be taken with or without food (see section 5.2).

Capsules may also be opened, and granules mixed with one tablespoon apple sauce for administration. After preparing the mixture, the medicinal product should be administered immediately.

Granules should not be chewed.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

PPI's, including DEXILANT are contraindicated with rilpivirine-containing products (see section 4.5)

Hypersensitivity reactions may include acute tubulointerstitial nephritis. See section 4.4

4.4 Special warnings and precautions for use

The possibility of malignant gastric tumour should be excluded when using DEXILANT because DEXILANT can mask the symptoms and delay the diagnosis.

Acute tubulointerstitial nephritis (see section 4.3)

Acute tubulointerstitial nephritis (TIN) has been observed in patients taking PPIs including DEXILANT. Acute tubulointerstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Acute tubulointerstitial nephritis may lead to chronic renal failure.

Healthcare professionals should frequently monitor renal function and check the urine for haematuria and/or proteinuria in patients on treatment with PPIs such as DEXILANT.

Discontinue DEXILANT if acute tubulointerstitial nephritis develops.

Co-administration of DEXILANT is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir or nelfinavir, due to significant reduction in their bioavailability (see section 4.5).

DEXILANT should be used with caution in patients with moderate hepatic dysfunction. DEXILANT is not recommended for patients with severe hepatic impairment (see sections 4.2 and 5.2).

DEXILANT, Treatment with dexlansoprazole may lead to slightly increased risk of gastrointestinal infections such as and *Clostridium difficile*.

Because of limited safety data for patients on treatment for longer than 6 months regular review of the treatment and a thorough risk/benefit assessment should regularly be performed in these patients.

Severe hypomagnesaemia has been reported in patients treated with PPIs like DEXILANT for at least three months, in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, delirium, convulsions, dizziness and ventricular arrhythmia can occur, but they may begin insidiously and be overlooked. Hypomagnesaemia may lead to hypocalcaemia and/or hypokalaemia (see section 4.8). In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI. For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g. diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.

Influence on Vitamin B-12 Absorption

DEXILANT, may reduce the absorption of vitamin B-12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B-12 absorption on long-term therapy or if respective clinical symptoms are observed.

DEXILANT may cause colitis. Cases of colitis have been reported infrequently for DEXILANT therefore in the case of severe or persistent diarrhoea discontinue DEXILANT.

DEXILANT, especially if used in high doses and over long durations (>1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in the presence of other recognised risk factors. Patients treated with DEXILANT for more than one year should take Vitamin D and calcium supplementation.

When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high dose methotrexate administration, a temporary withdrawal of DEXILANT may need to be considered.

As DEXILANT contains sucrose, patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Severe Cutaneous Adverse Reactions

Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and erythema multiforme have been reported in association with the use of PPIs (see section 4.8). Discontinue DEXILANT at the first signs or symptoms of severe cutaneous adverse reactions or other signs of hypersensitivity and consider further evaluation.

Subacute cutaneous lupus erythematosus (SCLE)

Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, DEXILANT should be discontinued. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.

Interference with laboratory tests

Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, DEXILANT treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults.

Effects of other medicinal products on DEXILANT

CYP2C19 and CYP3A4 have been shown to be involved in the metabolism of DEXILANT

Medicinal products which inhibit CYP2C19

Inhibitors of CYP2C19 (such as fluvoxamine) would likely increase the systemic exposure of DEXILANT

Medicinal products which induce CYP2C19 and CYP3A4

Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John's wort (*Hypericum perforatum*) may reduce the plasma concentrations of DEXILANT.

Others

Sucralfate/Antacids

Sucralfate/Antacids may decrease the bioavailability of DEXILANT. Therefore, DEXILANT should be taken at least 1 hour after taking these drugs.

Effects of DEXILANT on other medicinal products

Medicinal products with pH dependent absorption

DEXILANT may interfere with the absorption of medicinal products where gastric pH is critical to bioavailability HIV protease inhibitors

Co-administration of DEXILANT is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH, such as atazanavir or nelfinavir- due to significant reduction in their bioavailability (see section 4.4).

Ketoconazole, itraconazole and erlotinib

The absorption of ketoconazole, itraconazole and erlotinib from the gastrointestinal tract is enhanced by the presence of gastric acid. Administration of DEXILANT may result in sub-therapeutic concentrations of ketoconazole, itraconazole and erlotinib, and the combination should be avoided.

Digoxin

Co-administration of DEXILANT and digoxin may lead to increased digoxin plasma levels. The plasma levels of digoxin should therefore be monitored, and the dose of digoxin adjusted if necessary when initiating and ending DEXILANT treatment.

Medicinal products metabolised by P450 enzymes

In vitro studies have shown that DEXILANT is not likely to inhibit CYP isoforms 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1 or 3A4. As such, no clinically relevant interactions with medicinal products metabolised by these CYP enzymes would be expected. Furthermore, *in vivo* studies showed that DEXILANT did not have an impact on the pharmacokinetics of co-administered phenytoin (CYP2C9 substrate) or theophylline (CYP1A2 substrate). The subjects' CYP1A2 genotypes in the drug-drug interaction study with theophylline were not determined. Although *in vitro* studies demonstrated that DEXILANT has the potential to inhibit CYP2C19, an *in vivo* drug-drug interaction study in mainly CYP2C19 extensive and intermediate metabolisers has shown that DEXILANT does not affect the pharmacokinetics of diazepam (CYP2C19 substrate).

Tacrolimus

Co-administration of DEXILANT may increase the plasma concentrations of tacrolimus (a CYP3A and P-glycoprotein [P-gp] substrate), especially in transplant patients who are intermediate or poor metabolisers of CYP2C19. Monitoring of tacrolimus plasma concentrations is advised when concomitant treatment with DEXILANT is initiated or ended.

Warfarin

Co-administration of DEXILANT and warfarin did not result in any significant differences in the pharmacokinetics of warfarin or International Normalised Ratio (INR) compared to administration of warfarin with placebo. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin concomitantly. Patients treated with PPIs and warfarin concomitantly may need to be monitored for increases in INR and prothrombin time, especially when initiating or ending concomitant treatment.

Clopidogrel

Concomitant administration of DEXILANT (60 mg once daily) and clopidogrel 75 mg to healthy volunteers resulted in a reduction in the exposure to the active metabolite of clopidogrel (approximately 9 % decrease in AUC and 27 % decrease in C_{max}).

Co-administration of DEXILANT had no clinically meaningful effect on pharmacodynamics of clopidogrel. No dose adjustment of clopidogrel is necessary when administered with an approved dose of DEXILANT.

Methotrexate

Case reports, published population pharmacokinetic studies, and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high dose; see methotrexate prescribing information) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate possibly leading to methotrexate toxicities. Therefore, in settings where high-dose methotrexate is used a temporary withdrawal of DEXILANT may need to be considered.

However, no formal drug interaction studies of high-dose methotrexate with PPIs have been conducted.

PPI's including DEXILANT are contra-indicated with rilpivirine-containing products.

Medicinal products transported by P-glycoprotein

DEXILANT may inhibit the transport protein, P-gp

Others

No clinically significant interactions of DEXILANT with nonsteroidal anti-inflammatory drugs have been demonstrated, although no formal interactions studies have been performed.

4.6 Fertility, pregnancy and lactation

Pregnancy

There is limited amount of data from the use of DEXILANT in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of DEXILANT during pregnancy.

Breastfeeding

It is not known whether DEXILANT is excreted in human breast milk. Animal studies have shown excretion of lansoprazole in milk.

A risk to the newborns/infants cannot be excluded. DEXILANT should not be used during breastfeeding

Fertility

There was no evidence of impaired fertility following the administration of lansoprazole in animal studies (see section 5.3). Similar results could be expected with DEXILANT

4.7 Effects on ability to drive and use machines

Instances of dizziness, vertigo, visual disturbances and somnolence have been reported with DEXILANT. Patients who are experiencing these adverse events should not drive or use machines. Under these conditions the ability to react may be decreased.

4.8 Undesirable effects

Summary of the safety profile

Adults

DEXILANT at doses of 30, 60, or 90 mg has been evaluated for safety in clinical studies in patients treated for up to 1 year. In these clinical studies, adverse reactions associated with treatment with DEXILANT were mostly mild or moderate, with an overall incidence similar to placebo and lansoprazole. The most commonly reported adverse reactions were diarrhoea, abdominal pain, headache, nausea, abdominal discomfort, flatulence and constipation. The incidence of these adverse reactions was not affected by gender, age, or race.

Tabulated list of adverse reactions

Adverse reactions reported for DEXILANT (30 mg, 60 mg or 90 mg) in clinical studies and post- marketing experience are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common ($\geq 1/10$); common ($\geq 1/100$ to $< 1/10$); uncommon ($\geq 1/1\ 000$ to $< 1/100$); rare ($\geq 1/10\ 000$ to $< 1/1\ 000$); very rare ($< 1/10\ 000$); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

| System organ class | Common | Uncommon | Rare | Not known |
|--|--------|----------|------|--|
| Blood and lymphatic system disorders | | | | Autoimmune haemolytic anaemia ^{1,2} Idiopathic thrombocytopenic purpura ² |
| Immune system disorders | | | | Anaphylactic reaction ² Hypersensitivity ^{1,2} Anaphylactic shock ² |
| Metabolism and connective tissue disorders | | | | Hypomagnesaemia ² (see section 4.4) Hyponatraemia ² Hypocalcaemia ^{2,3} Hypokalaemia ^{2,3} |

| | | | | |
|---|---|---|----------------------------|-----------------------------|
| Musculoskeletal and connective tissue disorders | | Fracture of the hip, wrist or spine (see section 4.4) | | |
| Psychiatric disorders | | Insomnia Depression | Auditory hallucinations | Visual hallucinations |
| Nervous system disorders | Headache | Dizziness Altered taste | Convulsion Paraesthesia | |
| Eye disorders | | | Visual disturbance | Blurred vision ² |
| Ear and labyrinth disorders | | | Vertigo | Deafness ² |
| Vascular disorders | | Hypertension Hot flushes | | |
| Respiratory, thoracic and mediastinal disorders | | Cough | | |
| Gastrointestinal disorders | Diarrhoea ¹ Abdominal pain ¹ Nausea Abdominal discomfort Flatulence Constipation | Vomiting Dry mouth | Candidiasis | |

| | | | | |
|--|------------------------------|-------------------------------|--|---|
| | Fundic gland polyps (benign) | | | |
| Hepatobiliary disorders | | Liver function test abnormal | | Hepatitis drug-induced ² |
| Skin and subcutaneous tissue disorders | | Urticaria Pruritus Rash | | Subacute cutaneous lupus erythematosus (see section 4.4) Stevens-Johnson syndrome ² Toxic epidermal necrolysis ² Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) ² Erythema multiforme |
| Renal and urinary disorders | | | Tubulointerstitial nephritis ² (with possible progression that may lead to chronic renal failure) | |
| General disorders and | | Asthenia Appetite changes | | |

| | | | | |
|-----------------------------------|--|--|--|--|
| administration site conditions | | | | |
|-----------------------------------|--|--|--|--|

¹ see section 'Description of selected adverse reactions'

² adverse reactions that have been observed during post approval of dexlansoprazole (as these reactions are reported voluntarily from a population of uncertain size, frequency cannot be estimated from the available data)

³ Hypocalcaemia and/or hypokalaemia may be related to the occurrence of hypomagnesaemia (see section 4.4)

Description of selected adverse reactions

Diarrhoea and abdominal pain

In the Phase 3 clinical studies, the most commonly reported adverse reaction was diarrhoea (excluding infective diarrhoea), the majority of which were non serious. Overall, few subjects (2,4 %) prematurely discontinued due to an adverse reaction while receiving DEXILANT therapy. The most common ($\geq 0,5$ %) adverse reactions leading to premature discontinuation were diarrhoea, gastrointestinal and abdominal pains. Initial onset of diarrhoea and abdominal pain was independent of the duration of exposure, and the majority of these events were mild to moderate in severity. There were no apparent dose-related trends observed across DEXILANT doses for the incidence of these events.

Hypersensitivity

There have been post-marketing cases reporting serious hypersensitivity reactions. Hypersensitivity reactions were more frequently reported in females (74 %). The majority of the serious cases were managed with steroids and/or antihistamines and withdrawal of the medicinal product. Severe reactions of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Drug reaction with eosinophilia and systemic symptoms (DRESS) and erythema multiforme were reported in few patients.

Haemolytic anaemia

There have been few serious post-marketing reports of haemolytic anaemia after approximately four to seven months on DEXILANT 60 mg therapy.

Paediatric population

The safety profile for adolescents aged 12 to 17 years is similar to adults. In clinical studies of 166 adolescent patients, the only adverse reaction that occurred in more than one patient was abdominal pain. Additional adverse reactions, which occurred in one patient each, included diarrhoea, urticaria, dry mouth and headache.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the National Adverse Drug Event Monitoring Centre or Pharmacovigilance unit at SAHPRA, using the “**6.04 Adverse Drug Reactions Reporting Form**”, found online under SAHPRA’s publications: <https://www.sahpra.org.za/Publications/Index/8>. Additionally, suspected adverse reactions can be reported to DSO-ZA@takeda.com

4.9 Overdose

In the case of suspected overdose, the patient should be monitored. DEXILANT is not significantly eliminated by haemodialysis. If necessary, charcoal and symptomatic therapy is recommended.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

A.11.4.3 Medicines acting on the gastrointestinal tract

Mechanism of action

Dexlansoprazole is the R-enantiomer of lansoprazole. It is a gastric proton pump inhibitor. It inhibits the final stage of gastric acid formation by inhibiting the activity of H⁺/K⁺ ATPase of the parietal cells in the

stomach. The inhibition is dose-dependent and reversible, and the effect applies to both basal and stimulated secretion of gastric acid. Dexlansoprazole is concentrated in the parietal cells and becomes active in their acidic environment, whereupon it reacts with the sulphhydryl group of H⁺/K⁺ATPase causing inhibition of the enzyme activity.

Pharmacodynamic effects

Antisecretory activity

The antisecretory activity of dexlansoprazole T has been studied in healthy subjects taking dexlansoprazole 60 mg once daily for five days. The average intragastric pH was 4,55 for dexlansoprazole. The average percentage of time throughout the day in which the intragastric pH is maintained above 4 was 71 % (17 hours) with dexlansoprazole.

Serum gastrin effect

The effect of dexlansoprazole on serum gastrin concentrations was evaluated in patients in clinical trials up to 12 months. The mean fasting gastrin concentrations increased from baseline during treatment with dexlansoprazole 30 mg and 60 mg doses. In patients treated for more than 6 months, mean serum gastrin levels increased during approximately the first 3 months of treatment and were stable for the remainder of treatment.

Clinical efficacy and safety

Treatment of erosive reflux oesophagitis

Two multi-center, double-blind, active-controlled, randomised, 8-week studies were conducted in patients with endoscopically confirmed erosive reflux oesophagitis. Severity of the disease was classified based on the Los Angeles Classification Grading System (Grades A-D). A total of 4092 patients were enrolled and ranged in age from 18 to 90 years (median age 48 years) with 54 % male. Based on the Los Angeles Classification, 71 % of patients had Grades A and B erosive reflux oesophagitis (mild) and 29 % of patients had Grades C and D erosive reflux oesophagitis (moderate to severe) before treatment.

Dexlansoprazole 60 mg healed 92,3 % to 93,1 % of patients 8 weeks of treatment (primary).

In the second study, healing rates were 87,6 % and 90 % for dexlansoprazole 60 mg and 90 mg respectively.

Maintenance of healed erosive reflux oesophagitis

A multi-center, double-blind, placebo-controlled, randomised study was conducted in patients who successfully completed an erosive reflux oesophagitis study and showed endoscopically confirmed healed erosive reflux oesophagitis. A total of 445 patients were enrolled and ranged in age from 18 to 85 years (median age 49 years), with 52 % female.

Dexlansoprazole 30 mg and 60 mg demonstrated statistically significantly higher rates of maintenance of healed erosive reflux oesophagitis (74,9 % and 82,5 %, respectively) than placebo (27,2 %) at Month 6 ($p < 0,00001$).

For patients with more severe grades of erosive reflux oesophagitis (Grades C or D) before healing, Dexlansoprazole 30 mg and 60 mg also achieved high 6-month maintenance rates than placebo

Dexlansoprazole 30 mg and 60 mg achieved statistically significantly ($p < 0,00001$) greater percentages of heartburn relief during the study treatment period. The median percentages of 24-hour heartburn-free days were 96,1 %, 90,9 % and 28,6 % for DEXILANT 30 mg, 60 mg and placebo, respectively. The median percentages of nights without heartburn were 98,9 %, 96,2 % and 71,7 % for Dexlansoprazole 30 mg, 60 mg and placebo, respectively. In a second study (N=451) of Dexlansoprazole 60 mg and 90 mg versus placebo, Dexlansoprazole 60 mg showed similar results to the first study in the maintenance of healed erosive reflux oesophagitis and heartburn relief. Dexlansoprazole 90 mg did not provide additional clinical benefit over dexlansoprazole 60 mg.

Symptomatic non-erosive GORD

A multi-center, double-blind, placebo-controlled, randomised, 4-week study was conducted in patients with a diagnosis of symptomatic GORD made primarily by presentation of symptoms. These patients who identified heartburn as their primary symptom, had a history of heartburn for 6 months or longer, had heartburn on at least 4 of 7 days immediately prior to randomisation and had no esophageal erosions as confirmed by endoscopy. A total of 947 patients were enrolled and ranged in age from 18 to 86 years (median age 48 years) with 71 % female.

Dexlansoprazole 30 mg provided statistically significantly greater percent of days with heartburn-free 24-hour periods and percent of nights without heartburn (respectively 54,9 % and 80,8 %) over placebo (respectively 18,5 % and 51,7 %) as assessed by daily diary over 4 weeks. A higher percentage of patients on dexlansoprazole 30 mg had heartburn-free 24-hour periods compared to placebo through 4 weeks of treatment. Dexlansoprazole 60 mg had no additional clinical benefit over dexlansoprazole 30 mg.

Paediatric population

Treatment of erosive reflux oesophagitis, maintenance of healed erosive reflux oesophagitis and relief of heartburn

In a multi-center, 24-week study, 62 adolescents with a documented history of GORD for at least 3 months and endoscopically proven erosive reflux oesophagitis were treated with dexlansoprazole 60 mg once daily, for 8 weeks to evaluate safety and effectiveness. Patients ranged in age from 12 to 17 years (median age 15 years) with 61 % being male. Based on the Los Angeles Classification Grading Scale, 96,8 % of the erosive reflux oesophagitis patients had mild erosive reflux oesophagitis (Grades A and B), and 3,2 % of patients had moderate to severe erosive reflux oesophagitis (Grades C and D) before treatment. The erosive reflux oesophagitis healing rate in adolescents was 87,9 %, which is similar to adults for up to 8 weeks of treatment.

After the initial 8 weeks of treatment, patients with endoscopically confirmed healed erosive reflux oesophagitis were randomised to receive treatment with dexlansoprazole 30 mg or placebo, once daily for an additional 16 weeks. Eighty-two percent of patients treated with 30 mg of Dexlansoprazole remained healed over the four-month treatment period as confirmed by endoscopy versus 58 % for placebo.

During the 16-week maintenance period, the median percentage of 24-hour heartburn-free periods was 86,6 % for those receiving dexlansoprazole 30 mg compared to 68,1 % for those receiving placebo.

The results for maintenance of healing and relief of heartburn were similar to adults.

Symptomatic non-erosive GORD

In an uncontrolled, open-label, multi-center study, 104 adolescents with symptomatic non-erosive GORD were treated with dexlansoprazole 30 mg once daily, for 4 weeks to evaluate safety and effectiveness. Patients had a documented history of GORD symptoms for at least 3 months prior to screening, reported heartburn on at least three out of seven days during screening, and had no oesophageal erosions as confirmed by endoscopy. Patients ranged in age from 12 to 17 years (median age 15 years) with 70 %

being female. During the 4-week treatment period, the median percentage of 24-hour heartburn-free periods was 47,3 % which was similar to adults.

5.2 Pharmacokinetic properties

The formulation of dexlansoprazole utilising dual delayed release technology results in a dexlansoprazole plasma concentration-time profile with two distinct peaks; the first peak occurs 1 to 2 hours after administration, followed by a second peak within 4 to 5 hours.

Absorption

After oral administration of dexlansoprazole 30 mg or 60 mg to healthy subjects, mean C_{max} and AUC values of dexlansoprazole increased approximately dose proportionally. Peak plasma levels occur within 4 to 6 hours.

Distribution

Plasma protein binding of dexlansoprazole ranged from 96,1 % to 98,8 % in healthy subjects and was independent of concentration from 0,01 to 20 mcg per mL. The apparent volume of distribution after multiple doses in symptomatic GORD patients was 40,3 L.

Biotransformation

Dexlansoprazole is extensively metabolised in the liver by oxidation, reduction, and subsequent formation of sulfate, glucuronide and glutathione conjugates to inactive metabolites. Oxidative metabolites are formed by the cytochrome P450 (CYP) enzyme system including hydroxylation mainly by CYP2C19, and oxidation to the sulfone by CYP3A4. CYP2C19 is a polymorphic liver enzyme which exhibits three phenotypes in the metabolism of CYP2C19 substrates; extensive metabolisers (*1/*1), intermediate metabolisers (*1/mutant) and poor metabolisers (mutant/mutant). Systemic exposure of dexlansoprazole is generally higher in intermediate and poor metabolisers. Dexlansoprazole is the major circulating component in plasma, regardless of CYP2C19 metaboliser status. In CYP2C19 intermediate and extensive metabolisers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolisers dexlansoprazole sulfone is the major plasma metabolite.

Elimination

Following the administration of dexlansoprazole, no unchanged dexlansoprazole is excreted in urine.

Following the administration of [¹⁴C] dexlansoprazole to healthy male subjects, approximately 50,7 % of the administered radioactivity was excreted in urine and 47,6 % in the faeces. Apparent clearance in healthy subjects was 11,4 to 11,6 L/h, respectively, after 5-days of 30 or 60 mg once daily administration.

Linearity/non-linearity

Following a single and multiple daily dexlansoprazole 30 to 120 mg doses to healthy subjects, mean dexlansoprazole C_{max} and AUC values increased approximately dose proportionally over the entire dose range. The pharmacokinetics of dexlansoprazole was both dose- and time-independent, with an estimated terminal elimination half-life of approximately 1 to 2 hours. Therefore, little or no active substance accumulation was observed for dexlansoprazole after once daily doses of dexlansoprazole, as evidenced by similar C_{max} and AUC values after a single and multiple once-daily doses at steady- state.

Effect of food

Dexlansoprazole can be taken without regard to food or the timing of food. In food-effect studies in healthy subjects receiving dexlansoprazole, increases in C_{max} ranged from 12 % to 55 % and increases in AUC ranged from 9 % to 37 % under various fed conditions compared to fasting. However, no relevant differences with regard to intragastric pH were observed. An additional study showed that administration of 60 mg dexlansoprazole prior to consumption of breakfast, lunch, dinner or an evening snack did not have an effect on dexlansoprazole exposure, or a clinically relevant effect on 24-hour intragastric pH control.

Special patient populations

Elderly

In a study of male and female healthy subjects who received a single oral dose of dexlansoprazole 60 mg, the terminal elimination half-life of dexlansoprazole was statistically significantly longer in elderly subjects compared to younger subjects (2,23 and 1,5 hours, respectively). In addition, dexlansoprazole exhibited higher systemic exposure (AUC) in elderly subjects (34,5 % higher) than younger subjects. These

differences were not clinically relevant. A daily dose of 60 mg should not be exceeded in the elderly unless there are compelling clinical indications.

Renal impairment

Dexlansoprazole is extensively metabolised in the liver to inactive metabolites, and no parent active substance is recovered in the urine following an oral dose of dexlansoprazole. Therefore, the pharmacokinetics of dexlansoprazole are not expected to be altered in patients with renal impairment, and no studies were conducted in subjects with renal impairment (see section 4.4).

Hepatic impairment

In a study of patients with moderately impaired hepatic function who received a single oral dose of dexlansoprazole 60 mg, plasma exposure (AUC) of bound and unbound dexlansoprazole in the hepatic impairment group was approximately 2 times greater compared to subjects with normal hepatic function. This difference in exposure was not due to a difference in protein binding between the two liver function groups. No adjustment for dexlansoprazole is necessary for patients with mild hepatic impairment. dexlansoprazole 30 mg should be considered for patients with moderate hepatic impairment. No studies have been conducted in patients with severe hepatic impairment, the use of dexlansoprazole is not recommended for these patients (see section 4.4).

Paediatric population

The pharmacokinetics of dexlansoprazole were studied in 36 patients with symptomatic GORD aged 12 to 17 years in a multi-center study. Patients were randomised to receive dexlansoprazole 30 mg or 60 mg once daily for 7 days. In adolescents, dexlansoprazole mean C_{max} was 81 % to 105 % of the adult mean C_{max} value, mean AUC was 78 % to 88 % of the adult mean AUC value, and mean CL/F was 112 % to 132 % of the adult mean CL/F value. Overall, dexlansoprazole pharmacokinetics in patients aged 12 to 17 years were similar to those observed in healthy adults.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, toxicity to reproduction and development.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Capsule content

Silica, colloidal anhydrous

Hydroxypropylcellulose

Hypromellose

Low-substituted hydroxypropyl cellulose

Magnesium carbonate, heavy

Methacrylic acid-ethyl acrylate copolymer (1:1) dispersion 30 per cent (Methacrylic acid units, Ethyl acrylate units, Sodium laurilsulfate, Polysorbate 80)

Methacrylic acid-methyl methacrylate copolymer (1:1)

Methacrylic acid-methyl methacrylate copolymer (1:2)

Macrogol 8000

Polysorbate 80

Sucrose

Sugar spheres (Sucrose, Corn starch)

Talc

Titanium dioxide (E171)

Triethyl citrate

Capsule shell 30 mg

Carrageenan (E407)

Titanium dioxide (E171)

Hypromellose

Potassium chloride

Water, purified

Indigotine (E132)

Iron oxide, black (E172)

Capsule shell 60 mg

Carrageenan (E407)

Titanium dioxide (E171)

Hypromellose

Potassium chloride

Water, purified

Indigotine (E132)

Printing ink

Iron oxide, red (E172)

Iron oxide, yellow (E172)

Indigotine (E132)

Carnauba wax

Shellac

Glycerol mono-oleate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Do not store above 25°C.

6.5 Nature and contents of container

DEXILANT 30 mg: PVC/PE/polychlorotrifluoroethylene (PCTFE) - aluminium blister packs containing 14, 28, 56 or 98 capsules.

DEXILANT 60 mg: PVC/PE/polychlorotrifluoroethylene (PCTFE) - aluminium blister packs containing 14 or 28 capsules.

Not all pack sizes may be marketed

6.6 Special precautions for disposal and other handling

No special requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

TAKEDA (Pty) Ltd

Building A, Montecircle

64 Montecasino Boulevard

Fourways

2191

8. MARKETING AUTHORISATION NUMBER(S)

Dexilant 30 mg: 48/11.4.3/0695

Dexilant 60 mg: 48/11.4.3/0696

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 17th August 2021

10. DATE OF REVISION OF THE TEXT

22 April 2024